Topics will include descriptions of the following:
- Preferred hepatocyte culture morphology and confluency
- Plating formats and treatment options
- Appropriate responses to positive control inducers for CYP and UGT enzymes
- Data interpretation based on FDA and EMA recommendations
The webinars will end with open questions.
Gladys Verelst, Marketing specialist at tebu-bio (Le Perray-en-Yvelines, France) says: “We are very pleased to be able to offer our clients throughout Europe access to these high quality ADME-TOX products and to show researchers through this technical insight, the added value of working with reliable products for in vitro enzyme induction studies in particular".
To find out more about these products and webinar, visit www.tebu-bio.com or contact Gladys Verelst (gladys.verelst@
About XenoTech LLC
XenoTech, founded by Dr. Andrew Parkinson in 1994, is a Contract Research Organisation with unparalleled experience and expertise in evaluating drug candidates as substrates, inhibitors and inducers of cytochrome P450 enzymes. The company offers an extensive selection of products for drug metabolism research as well as a variety of in vitro contract studies for drug candidate evaluation. The company can also prepare and deliver custom-designed products and services in response to client requests. XenoTech is based in Lenexa, Kansas, U.S.A. and has approximately 110 employees. For additional information, please refer to the company's web site at www.xenotechllc.com.
# # #
tebu-bio is an expert in the supply & distribution of innovative Life Sciences Lab Services & Reagents throughout Europe in numerous fields including target discovery and validation, assay development and screening and ADME-Tox studies. Their own laboratories also provide R&D contract services. www.tebu-bio.com offers access to the most innovative range of over 650 000 references.